RT Journal Article
SR Electronic
T1 NSAID Activated Gene (NAG-1) plays a role in the impairing effects of cyclooxygenase inhibitors on gastric ulcer healing
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP jpet.111.190116
DO 10.1124/jpet.111.190116
A1 Colucci, Rocchina
A1 Antonioli, Luca
A1 Bernardini, Nunzia
A1 Ippolito, Chiara
A1 Segnani, Cristina
A1 Awwad, Oriana
A1 Tuccori, Marco
A1 Blandizzi, Corrado
A1 Scarpignato, Carmelo
A1 Fornai, Matteo
YR 2012
UL http://jpet.aspetjournals.org/content/early/2012/04/10/jpet.111.190116.abstract
AB Non-steroidal anti-inflammatory drugs (NSAIDs) can impair gastric ulcer healing. This study investigates the involvement of NSAID-activated gene-1 (NAG-1) in ulcer repair impairment by cyclooxygenase (COX) inhibitors. Gastric ulcers were induced in rats by acetic acid. Four days later, animals received daily intragastric indomethacin (non-selective COX-1/COX-2 inhibitor, 1 mg/kg), SC-560 (selective COX-1 inhibitor, 2.5 mg/kg), DFU (selective COX-2 inhibitor, 5 mg/kg), celecoxib (selective COX-2 inhibitor, 1 mg/kg) and valdecoxib (selective COX-2 inhibitor, 1 mg/kg), for 1, 3 or 7 days. Ulcerated tissues were processed to assess: 1) COX-1, COX-2, NAG-1, proliferating cell nuclear antigen (PCNA) and activated caspase-3 expression; 2) ulcer area; 3) prostaglandin E2. COX-1 expression in ulcerated tissues was decreased, while COX-2 expression was enhanced. Ulcer healing was delayed by indomethacin, DFU and SC-560, but not by celecoxib and valdecoxib. Ulcer PGE2 levels were decreased by SC-560, DFU, celecoxib, valdecoxib and indomethacin. NAG-1 was over-expressed in ulcerated tissues, and further enhanced by indomethacin, DFU and SC-560, but not by celecoxib or valdecoxib. PCNA expression in ulcerated areas was reduced by indomethacin, but not by other test drugs. The expression of activated caspase-3 in ulcers was increased, and enhanced further by indomethacin, DFU or SC-560, but not by celecoxib or valdecoxib. These findings indicate that: 1) COX inhibitors exert differential impairing effects on gastric ulcer healing, through mechanisms unrelated to the inhibition of COX isoforms and prostaglandin production; 2) NAG-1 induction, followed by activation of proapoptotic pathways, can contribute to the impairing effects of COX inhibitors on ulcer healing